Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
Environ Health Perspect. 1993 Apr; 100: 9–20.
PMCID: PMC1519586
Research Article

Mechanisms of multistep carcinogenesis and carcinogen risk assessment.

Abstract

Many different types of chemical exposures can increase the incidence of tumors in animals and humans, but usually a long period of time is required before the carcinogenic risk of an exposure is manifested. Both of these observations can be explained by a multistep/multigene model of carcinogenesis. In this model, a normal cell evolves into a cancer cell as the result of heritable changes in multiple, independent genes. The two-stage model of initiation and promotion for chemical carcinogenesis has provided a paradigm by which chemicals can act by qualitatively different mechanisms, but the process of carcinogenesis is now recognized as more complex than simply initiation and promotion. Even a three-stage model of initiation, promotion, and progression, which can be operationally defined, is not adequate to describe the carcinogenic process. The number of genes altered in a cancer cell compared to a normal cell is not known; recent evidence suggests that 3-10 genetic events are involved in common adult malignancies in humans. Two distinct classes of genes, protooncogenes and tumor-suppressor genes, are involved in the cancer process. Multiple oncogenes may be activated in a tumor, while multiple tumor-suppressor genes may be inactivated. Identification of the genes involved in carcinogenesis and elucidation of the mechanisms of their activation or inactivation allows a better understanding of how chemical carcinogens influence the process of neoplastic evolution. The findings of multiple genetic changes (including point mutations, chromosomal translocations, deletions, gene amplification, and numerical chromosome changes) in activated protooncogenes and inactivated tumor-suppressor genes provide experimental support for Boveri's somatic mutation theory of carcinogenesis. In addition to mutagenic mechanisms, chemicals may heritably alter cells by epigenetic mechanisms and enhance the clonal expansion of altered cells. Most chemical carcinogens operate via a combination of mechanisms, and even their primary mechanism of action may vary depending on the target tissues. The classification of chemicals by mechanism of action or by nongenotoxic or genotoxic activity has certain inherent difficulties because no classification of chemicals is exhaustive or definitive.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (2.5M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Pitot HC, Goldsworthy T, Moran S. The natural history of carcinogenesis: implications of experimental carcinogenesis in the genesis of human cancer. J Supramol Struct Cell Biochem. 1981;17(2):133–146. [PubMed]
  • Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature. 1986 Jul 3;322(6074):78–80. [PubMed]
  • Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barbacid M. Direct mutagenesis of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature. 315(6018):382–385. [PubMed]
  • Wiseman RW, Stowers SJ, Miller EC, Anderson MW, Miller JA. Activating mutations of the c-Ha-ras protooncogene in chemically induced hepatomas of the male B6C3 F1 mouse. Proc Natl Acad Sci U S A. 1986 Aug;83(16):5825–5829. [PMC free article] [PubMed]
  • Reynolds SH, Stowers SJ, Patterson RM, Maronpot RR, Aaronson SA, Anderson MW. Activated oncogenes in B6C3F1 mouse liver tumors: implications for risk assessment. Science. 1987 Sep 11;237(4820):1309–1316. [PubMed]
  • Barrett JC, Wiseman RW. Cellular and molecular mechanisms of multistep carcinogenesis: relevance to carcinogen risk assessment. Environ Health Perspect. 1987 Dec;76:65–70. [PMC free article] [PubMed]
  • Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res. 1989 Jul 15;49(14):3713–3721. [PubMed]
  • Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. [PubMed]
  • Boyd JA, Barrett JC. Genetic and cellular basis of multistep carcinogenesis. Pharmacol Ther. 1990;46(3):469–486. [PubMed]
  • Callahan R, Campbell G. Mutations in human breast cancer: an overview. J Natl Cancer Inst. 1989 Dec 6;81(23):1780–1786. [PubMed]
  • Weston A, Willey JC, Modali R, Sugimura H, McDowell EM, Resau J, Light B, Haugen A, Mann DL, Trump BF, et al. Differential DNA sequence deletions from chromosomes 3, 11, 13, and 17 in squamous-cell carcinoma, large-cell carcinoma, and adenocarcinoma of the human lung. Proc Natl Acad Sci U S A. 1989 Jul;86(13):5099–5103. [PMC free article] [PubMed]
  • Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988 Sep 1;319(9):525–532. [PubMed]
  • Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. Allelotype of colorectal carcinomas. Science. 1989 Apr 14;244(4901):207–211. [PubMed]
  • Hennings H, Shores R, Wenk ML, Spangler EF, Tarone R, Yuspa SH. Malignant conversion of mouse skin tumours is increased by tumour initiators and unaffected by tumour promoters. Nature. 1983 Jul 7;304(5921):67–69. [PubMed]
  • Weinberg RA. The action of oncogenes in the cytoplasm and nucleus. Science. 1985 Nov 15;230(4727):770–776. [PubMed]
  • Bishop JM. The molecular genetics of cancer. Science. 1987 Jan 16;235(4786):305–311. [PubMed]
  • Vesselinovitch SD, Rao KV, Mihailovich N. Neoplastic response of mouse tissues during perinatal age periods and its significance in chemical carcinogenesis. Natl Cancer Inst Monogr. 1979 May;(51):239–250. [PubMed]
  • SHUBIK P. The growth potentialities of induced skin tumors in mice; the effects of different methods of chemical carcinogenesis. Cancer Res. 1950 Nov;10(11):713–717. [PubMed]
  • Fujiki H, Suganuma M, Matsukura N, Sugimura T, Takayama S. Teleocidin from Streptomyces is a potent promoter of mouse skin carcinogenesis. Carcinogenesis. 1982;3(8):895–898. [PubMed]
  • Burns F, Albert R, Altshuler B, Morris E. Approach to risk assessment for genotoxic carcinogens based on data from the mouse skin initiation-promotion model. Environ Health Perspect. 1983 Apr;50:309–320. [PMC free article] [PubMed]
  • Scribner JD, Scribner NK, McKnight B, Mottet NK. Evidence for a new model of tumor progression from carcinogenesis and tumor promotion studies with 7-bromomethylbenz[a]anthracene. Cancer Res. 1983 May;43(5):2034–2041. [PubMed]
  • Hennings H, Shores R, Mitchell P, Spangler EF, Yuspa SH. Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis. 1985 Nov;6(11):1607–1610. [PubMed]
  • O'Connell JF, Klein-Szanto AJ, Digiovanni DM, Fries JW, Slaga TJ. Malignant progression of mouse skin papillomas treated with ethylnitrosourea, N-methyl-N'-nitro-N-nitrosoguanidine, or 12-O-tetradecanoylphorbol-13-acetate. Cancer Lett. 1986 Mar;30(3):269–274. [PubMed]
  • O'Connell JF, Klein-Szanto AJ, DiGiovanni DM, Fries JW, Slaga TJ. Enhanced malignant progression of mouse skin tumors by the free-radical generator benzoyl peroxide. Cancer Res. 1986 Jun;46(6):2863–2865. [PubMed]
  • Aldaz CM, Conti CJ, Klein-Szanto AJ, Slaga TJ. Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: relevance to malignancy. Proc Natl Acad Sci U S A. 1987 Apr;84(7):2029–2032. [PMC free article] [PubMed]
  • Conti CJ, Aldaz CM, O'Connell J, Klein-Szanto AJ, Slaga TJ. Aneuploidy, an early event in mouse skin tumor development. Carcinogenesis. 1986 Nov;7(11):1845–1848. [PubMed]
  • Potter VR. A new protocol and its rationale for the study of initiation and promotion of carcinogenesis in rat liver. Carcinogenesis. 1981;2(12):1375–1379. [PubMed]
  • Ishinishi N, Yamamoto A, Hisanaga A, Inamasu T. Tumorigenicity of arsenic trioxide to the lung in Syrian golden hamsters by intermittent instillations. Cancer Lett. 1983 Dec;21(2):141–147. [PubMed]
  • Pershagen G, Nordberg G, Björklund NE. Carcinomas of the respiratory tract in hamsters given arsenic trioxide and/or benzo[a]pyrene by the pulmonary route. Environ Res. 1984 Aug;34(2):227–241. [PubMed]
  • BARONI C, VAN ESCHG, SAFFIOTTI U. CARCINOGENESIS TESTS OF TWO INORGANIC ARSENICALS. Arch Environ Health. 1963 Dec;7:668–674. [PubMed]
  • Brown CC, Chu KC. Implications of the multistage theory of carcinogenesis applied to occupational arsenic exposure. J Natl Cancer Inst. 1983 Mar;70(3):455–463. [PubMed]
  • Boutwell RK. The function and mechanism of promoters of carcinogenesis. CRC Crit Rev Toxicol. 1974 Jan;2(4):419–443. [PubMed]
  • Lee TC, Tanaka N, Lamb PW, Gilmer TM, Barrett JC. Induction of gene amplification by arsenic. Science. 1988 Jul 1;241(4861):79–81. [PubMed]
  • Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene N-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4940–4944. [PMC free article] [PubMed]
  • Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984 Jun 8;224(4653):1121–1124. [PubMed]
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. [PubMed]
  • Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707–712. [PubMed]
  • Shelby MD. The genetic toxicity of human carcinogens and its implications. Mutat Res. 1988 Jan;204(1):3–15. [PubMed]
  • Shelby MD, Zeiger E. Activity of human carcinogens in the Salmonella and rodent bone-marrow cytogenetics tests. Mutat Res. 1990 Jun-Aug;234(3-4):257–261. [PubMed]
  • Ashby J, Tennant RW, Zeiger E, Stasiewicz S. Classification according to chemical structure, mutagenicity to Salmonella and level of carcinogenicity of a further 42 chemicals tested for carcinogenicity by the U.S. National Toxicology Program. Mutat Res. 1989 Jun;223(2):73–103. [PubMed]
  • Barrett JC, Lamb PW, Wiseman RW. Multiple mechanisms for the carcinogenic effects of asbestos and other mineral fibers. Environ Health Perspect. 1989 May;81:81–89. [PMC free article] [PubMed]
  • Topping DC, Nettesheim P. Two-stage carcinogenesis studies with asbestos in Fischer 344 rats. J Natl Cancer Inst. 1980 Sep;65(3):627–630. [PubMed]
  • Mossman BT, Marsh JP. Evidence supporting a role for active oxygen species in asbestos-induced toxicity and lung disease. Environ Health Perspect. 1989 May;81:91–94. [PMC free article] [PubMed]
  • Walker C, Everitt J, Barrett JC. Possible cellular and molecular mechanisms for asbestos carcinogenicity. Am J Ind Med. 1992;21(2):253–273. [PubMed]
  • Ishinishi N, Yamamoto A, Hisanaga A, Inamasu T. Tumorigenicity of arsenic trioxide to the lung in Syrian golden hamsters by intermittent instillations. Cancer Lett. 1983 Dec;21(2):141–147. [PubMed]
  • Jaurand MC. Particulate-state carcinogenesis: a survey of recent studies on the mechanisms of action of fibres. IARC Sci Publ. 1989;(90):54–73. [PubMed]
  • Hesterberg TW, Barrett JC. Dependence of asbestos- and mineral dust-induced transformation of mammalian cells in culture on fiber dimension. Cancer Res. 1984 May;44(5):2170–2180. [PubMed]
  • Hesterberg TW, Barrett JC. Induction by asbestos fibers of anaphase abnormalities: mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis. 1985 Mar;6(3):473–475. [PubMed]
  • Oshimura M, Hesterberg TW, Tsutsui T, Barrett JC. Correlation of asbestos-induced cytogenetic effects with cell transformation of Syrian hamster embryo cells in culture. Cancer Res. 1984 Nov;44(11):5017–5022. [PubMed]
  • Oshimura M, Hesterberg TW, Barrett JC. An early, nonrandom karyotypic change in immortal Syrian hamster cell lines transformed by asbestos: trisomy of chromosome 11. Cancer Genet Cytogenet. 1986 Jul;22(3):225–237. [PubMed]
  • Sugawara O, Oshimura M, Koi M, Annab LA, Barrett JC. Induction of cellular senescence in immortalized cells by human chromosome 1. Science. 1990 Feb 9;247(4943):707–710. [PubMed]
  • Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res. 1990 Dec 1;50(23):7415–7421. [PubMed]
  • Herbst AL, Poskanzer DC, Robboy SJ, Friedlander L, Scully RE. Prenatal exposure to stilbestrol. A prospective comparison of exposed female offspring with unexposed controls. N Engl J Med. 1975 Feb 13;292(7):334–339. [PubMed]
  • Barrett JC, Huff J. Cellular and molecular mechanisms of chemically induced renal carcinogenesis. Ren Fail. 1991;13(4):211–225. [PubMed]
  • Forsberg JG. Developmental mechanism of estrogen-induced irreversible changes in the mouse cervicovaginal epithelium. Natl Cancer Inst Monogr. 1979 May;(51):41–56. [PubMed]
  • McLachlan JA, Wong A, Degen GH, Barrett JC. Morphologic and neoplastic transformation of Syrian hamster embryo fibroblasts by diethylstilbestrol and its analogs. Cancer Res. 1982 Aug;42(8):3040–3045. [PubMed]
  • Liehr JG. 2-Fluoroestradiol. Separation of estrogenicity from carcinogenicity. Mol Pharmacol. 1983 Mar;23(2):278–281. [PubMed]
  • Barrett JC, Wong A, McLachlan JA. Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. Science. 1981 Jun 19;212(4501):1402–1404. [PubMed]
  • Tsutsui T, Maizumi H, McLachlan JA, Barrett JC. Aneuploidy induction and cell transformation by diethylstilbestrol: a possible chromosomal mechanism in carcinogenesis. Cancer Res. 1983 Aug;43(8):3814–3821. [PubMed]
  • Tsutsui T, Degen GH, Schiffmann D, Wong A, Maizumi H, McLachlan JA, Barrett JC. Dependence on exogenous metabolic activation for induction of unscheduled DNA synthesis in Syrian hamster embryo cells by diethylstilbestrol and related compounds. Cancer Res. 1984 Jan;44(1):184–189. [PubMed]
  • Sato Y, Murai T, Tsumuraya M, Saitô H, Kodama M. Disruptive effect of diethylstilbestrol on microtubules. Gan. 1984 Dec;75(12):1046–1048. [PubMed]
  • Sharp DC, Parry JM. Diethylstilboestrol: the binding and effects of diethylstilboestrol upon the polymerisation and depolymerisation of purified microtubule protein in vitro. Carcinogenesis. 1985 Jun;6(6):865–871. [PubMed]
  • Tucker RW, Barrett JC. Deceased numbers of spindle and cytoplasmic microtubules in hamster embryo cells treated with a carcinogen, diethylstilbestrol. Cancer Res. 1986 Apr;46(4 Pt 2):2088–2095. [PubMed]
  • Barrett JC, Hesterberg TW, Oshimura M, Tsutsui T. Role of chemically induced mutagenic events in neoplastic transformation of Syrian hamster embryo cells. Carcinog Compr Surv. 1985;9:123–137. [PubMed]
  • Tsutsui T, Maizumi H, Barrett JC. Amitrole-induced cell transformation and gene mutations in Syrian hamster embryo cells in culture. Mutat Res. 1984 Aug;140(4):205–207. [PubMed]
  • Barrett JC, Hesterberg TW, Thomassen DG. Use of cell transformation systems for carcinogenicity testing and mechanistic studies of carcinogenesis. Pharmacol Rev. 1984 Jun;36(2 Suppl):53S–70S. [PubMed]
  • Oshimura M, Barrett JC. Chemically induced aneuploidy in mammalian cells: mechanisms and biological significance in cancer. Environ Mutagen. 1986;8(1):129–159. [PubMed]
  • Huff JE, Haseman JK, DeMarini DM, Eustis S, Maronpot RR, Peters AC, Persing RL, Chrisp CE, Jacobs AC. Multiple-site carcinogenicity of benzene in Fischer 344 rats and B6C3F1 mice. Environ Health Perspect. 1989 Jul;82:125–163. [PMC free article] [PubMed]
  • Lee TC, Oshimura M, Barrett JC. Comparison of arsenic-induced cell transformation, cytotoxicity, mutation and cytogenetic effects in Syrian hamster embryo cells in culture. Carcinogenesis. 1985 Oct;6(10):1421–1426. [PubMed]
  • Weisburger JH, Williams GM. Carcinogen testing: current problems and new approaches. Science. 1981 Oct 23;214(4519):401–407. [PubMed]
  • Toman Z, Dambly C, Radman M. Induction of a stable, heritable epigenetic change by mutagenic carcinogens: a new test system. IARC Sci Publ. 1980;(27):243–255. [PubMed]
  • Loeb LA. Endogenous carcinogenesis: molecular oncology into the twenty-first century--presidential address. Cancer Res. 1989 Oct 15;49(20):5489–5496. [PubMed]
  • Ledda-Columbano GM, Columbano A, Curto M, Ennas MG, Coni P, Sarma DS, Pani P. Further evidence that mitogen-induced cell proliferation does not support the formation of enzyme-altered islands in rat liver by carcinogens. Carcinogenesis. 1989 May;10(5):847–850. [PubMed]
  • Hoel DG, Haseman JK, Hogan MD, Huff J, McConnell EE. The impact of toxicity on carcinogenicity studies: implications for risk assessment. Carcinogenesis. 1988 Nov;9(11):2045–2052. [PubMed]
  • Melnick RL. An alternative hypothesis on the role of chemically induced protein droplet (alpha 2u-globulin) nephropathy in renal carcinogenesis. Regul Toxicol Pharmacol. 1992 Oct;16(2):111–125. [PubMed]
  • Dotto GP, Weinberg RA, Ariza A. Malignant transformation of mouse primary keratinocytes by Harvey sarcoma virus and its modulation by surrounding normal cells. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6389–6393. [PMC free article] [PubMed]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science